From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging (168 visite)
Br J Haematol (ISSN: 0007-1048, 0007-1048linking, 1365-2141electronic), 2012 Sep; 158(3): 415-418.
Tipo di articolo: Letter, Research Support, Non-U. S. Gov'T,
Impact factor: 4.942, Impact factor a 5 anni: 4.726
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84863857069&partnerID=40&md5=081c04aaa783e08e73b6dfc7d4670397
Parole chiave: Eculizumab, Iron Metabolism, Iron Overload, Paroxysmal Nocturnal Haemoglobinuria, Complement Component C3, Ferritin, Hemosiderin, Abnormal Urine Composition, Adolescent, Adult, Clinical Article, Drug Response, Female, Ferritin Blood Level, Hemosiderinuria, Human, Hyperferritinemia, Kidney, Kidney Hemosiderosis, Letter, Liver, Liver Hemosiderosis, Nuclear Magnetic Resonance Imaging, Paroxysmal Nocturnal Hemoglobinuria, Priority Journal, Side Effect, Spleen, Antibodies, Monoclonal, Humanized, Middle Aged, Treatment Outcome, Young Adult, Humanized Therapeutic Use, Paroxysmal Blood Drug Therapy Immunology, Hemosiderin Urine, Iron Overload Blood, Magnetic Resonance Imaging Methods,
Affiliazioni:
*** IBB - CNR ***
Division of Haematology, Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy
Department of Radiology, Federico II University, Naples, Italy
Department of Haematology, University of Pavia Medical School, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
Department of Cellular Biotechnologies and Haematology, Università La Sapienza, Rome, Italy
Core Research Laboratory, Istituto Toscano Tumori, Florence, Italy
Department of Internal Medicine, Federico II University, Naples, Italy
Riferimenti:
Deugnier, Y., Turlin, B., Pathology of hepatic iron overload (2007) World Journal of Gastroenterology, 13, pp. 4755-476
Gandon, Y., Guyader, D., Heautot, J.F., Reda, M.I., Yaouanq, J., Buhé, T., Brissot, P., Deugnier, Y., Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging (1994) Radiology, 193, pp. 533-538
Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socié, G., Muus, P., Röth, A., Luzzatto, L., The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria (2006) New England Journal of Medicine, 355, pp. 1233-1243
Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., Mitchell, L.D., Hillmen, P., Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival (2011) Blood, 117, pp. 6786-6792
Mathieu, D., Rahmouni, A., Villeneuve, P., Anglade, M.C., Rochant, H., Vasile, N., Impact of magnetic resonance imaging on the diagnosis of abdominal complications of paroxysmal nocturnal hemoglobinuria (1995) Blood, 85, pp. 3283-3288
Parker, C., Omine, M., Richards, S., Nishimura, J., Bessler, M., Ware, R., Hillmen, P., Socié, G., Diagnosis and management of paroxysmal nocturnal hemoglobinuria (2005) Blood, 106, pp. 3699-3709. , International PNH Interest Group
Risitano, A.M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Rotoli, B., Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab (2009) Blood, 113, pp. 4094-4100
Risitano, A.M., Seneca, E., Marando, L., Imbraco, M., Soscia, E., Soscia, F., Micol Pizzuti, L., Rotoli, B., From renal siderosis due to perpetual hemosiderinuria to possible liver overload due to extravascular hemolysis: changes in iron metabolism in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab (2009) Blood, 114, p. 4031. , abs)
Risitano, A.M., Perna, F., Selleri, C., Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3 (2011) Mini Reviews in Medicinal Chemistry, 11, pp. 528-535
Röth, A., Hock, C., Konik, A., Christoph, S., Dührsen, U., Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena (2011) International Journal of Hematology, 93, pp. 704-714
Kelly, R. J., Hill, A., Arnold, L. M., Brooksbank, G. L., Richards, S. J., Cullen, M., Mitchell, L. D., Hillmen, P., Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival (2011) Blood, 117, pp. 6786-6792
Risitano, A. M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Rotoli, B., Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab (2009) Blood, 113, pp. 4094-4100
Risitano, A. M., Seneca, E., Marando, L., Imbraco, M., Soscia, E., Soscia, F., Micol Pizzuti, L., Rotoli, B., From renal siderosis due to perpetual hemosiderinuria to possible liver overload due to extravascular hemolysis: changes in iron metabolism in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab (2009) Blood, 114, p. 4031. , abs)
Risitano, A. M., Perna, F., Selleri, C., Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3 (2011) Mini Reviews in Medicinal Chemistry, 11, pp. 528-535
R th, A., Hock, C., Konik, A., Christoph, S., D hrsen, U., Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena (2011) International Journal of Hematology, 93, pp. 704-714
Br J Haematol (ISSN: 0007-1048, 0007-1048linking, 1365-2141electronic), 2012 Sep; 158(3): 415-418.
Tipo di articolo: Letter, Research Support, Non-U. S. Gov'T,
Impact factor: 4.942, Impact factor a 5 anni: 4.726
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84863857069&partnerID=40&md5=081c04aaa783e08e73b6dfc7d4670397
Parole chiave: Eculizumab, Iron Metabolism, Iron Overload, Paroxysmal Nocturnal Haemoglobinuria, Complement Component C3, Ferritin, Hemosiderin, Abnormal Urine Composition, Adolescent, Adult, Clinical Article, Drug Response, Female, Ferritin Blood Level, Hemosiderinuria, Human, Hyperferritinemia, Kidney, Kidney Hemosiderosis, Letter, Liver, Liver Hemosiderosis, Nuclear Magnetic Resonance Imaging, Paroxysmal Nocturnal Hemoglobinuria, Priority Journal, Side Effect, Spleen, Antibodies, Monoclonal, Humanized, Middle Aged, Treatment Outcome, Young Adult, Humanized Therapeutic Use, Paroxysmal Blood Drug Therapy Immunology, Hemosiderin Urine, Iron Overload Blood, Magnetic Resonance Imaging Methods,
Affiliazioni:
*** IBB - CNR ***
Division of Haematology, Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy
Department of Radiology, Federico II University, Naples, Italy
Department of Haematology, University of Pavia Medical School, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
Department of Cellular Biotechnologies and Haematology, Università La Sapienza, Rome, Italy
Core Research Laboratory, Istituto Toscano Tumori, Florence, Italy
Department of Internal Medicine, Federico II University, Naples, Italy
Riferimenti:
Deugnier, Y., Turlin, B., Pathology of hepatic iron overload (2007) World Journal of Gastroenterology, 13, pp. 4755-476
Gandon, Y., Guyader, D., Heautot, J.F., Reda, M.I., Yaouanq, J., Buhé, T., Brissot, P., Deugnier, Y., Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging (1994) Radiology, 193, pp. 533-538
Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socié, G., Muus, P., Röth, A., Luzzatto, L., The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria (2006) New England Journal of Medicine, 355, pp. 1233-1243
Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., Mitchell, L.D., Hillmen, P., Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival (2011) Blood, 117, pp. 6786-6792
Mathieu, D., Rahmouni, A., Villeneuve, P., Anglade, M.C., Rochant, H., Vasile, N., Impact of magnetic resonance imaging on the diagnosis of abdominal complications of paroxysmal nocturnal hemoglobinuria (1995) Blood, 85, pp. 3283-3288
Parker, C., Omine, M., Richards, S., Nishimura, J., Bessler, M., Ware, R., Hillmen, P., Socié, G., Diagnosis and management of paroxysmal nocturnal hemoglobinuria (2005) Blood, 106, pp. 3699-3709. , International PNH Interest Group
Risitano, A.M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Rotoli, B., Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab (2009) Blood, 113, pp. 4094-4100
Risitano, A.M., Seneca, E., Marando, L., Imbraco, M., Soscia, E., Soscia, F., Micol Pizzuti, L., Rotoli, B., From renal siderosis due to perpetual hemosiderinuria to possible liver overload due to extravascular hemolysis: changes in iron metabolism in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab (2009) Blood, 114, p. 4031. , abs)
Risitano, A.M., Perna, F., Selleri, C., Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3 (2011) Mini Reviews in Medicinal Chemistry, 11, pp. 528-535
Röth, A., Hock, C., Konik, A., Christoph, S., Dührsen, U., Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena (2011) International Journal of Hematology, 93, pp. 704-714
Kelly, R. J., Hill, A., Arnold, L. M., Brooksbank, G. L., Richards, S. J., Cullen, M., Mitchell, L. D., Hillmen, P., Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival (2011) Blood, 117, pp. 6786-6792
Risitano, A. M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Rotoli, B., Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab (2009) Blood, 113, pp. 4094-4100
Risitano, A. M., Seneca, E., Marando, L., Imbraco, M., Soscia, E., Soscia, F., Micol Pizzuti, L., Rotoli, B., From renal siderosis due to perpetual hemosiderinuria to possible liver overload due to extravascular hemolysis: changes in iron metabolism in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab (2009) Blood, 114, p. 4031. , abs)
Risitano, A. M., Perna, F., Selleri, C., Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3 (2011) Mini Reviews in Medicinal Chemistry, 11, pp. 528-535
R th, A., Hock, C., Konik, A., Christoph, S., D hrsen, U., Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena (2011) International Journal of Hematology, 93, pp. 704-714
Non disponibile.
Nessun risultato. |
Nessun risultato. |
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Cutrin JC, Alberti D, Bernacchioni C, Ciambellotti S, Turano P, Luchinat C, Crich SG, Aime S
* Cancer cell death induced by ferritins and the peculiar role of their labile iron pool (82 visite)
Oncotarget, 2018; N/D: N/D-N/D.
Impact Factor: 5.168
Dettagli Esporta in BibTeX Esporta in EndNote
Ferraro G, Ciambellotti S, Messori L, Merlino A
* Cisplatin Binding Sites in Human H-Chain Ferritin (106 visite)
Inorg Chem (ISSN: 0020-1669, 1520-510x), 2017 Aug 7; 56(15): 9064-9070.
Impact Factor: 4.7
Dettagli Esporta in BibTeX Esporta in EndNote
Zanzoni S, Pagano K, D'Onofrio M, Assfalg M, Ciambellotti S, Bernacchioni C, Turano P, Aime S, Ragona L, Molinari H
* Unsaturated Long-Chain Fatty Acids Are Preferred Ferritin Ligands That Enhance Iron Biomineralization (62 visite)
Chemistry, 2017 Jul; N/D: N/D-N/D.
Impact Factor: 5.16
Dettagli Esporta in BibTeX Esporta in EndNote
Pontillo N, Ferraro G, Helliwell JR, Amoresano A, Merlino A
* X-ray Structure of the Carboplatin-Loaded Apo-Ferritin Nanocage (110 visite)
Acs Med Chem Lett (ISSN: 1948-5875), 2017 Feb 28; 8(4): 433-437.
Impact Factor: 3.794
Dettagli Esporta in BibTeX Esporta in EndNote
Pontillo N, Pane F, Messori L, Amoresano A, Merlino A
* Cisplatin encapsulation within a ferritin nanocage: A high-resolution crystallographic study (121 visite)
Chem Commun (ISSN: 1359-7345, 1364-548x, 1364-548xelectronic), 2016; 52(22): 4136-4139.
Impact Factor: 6.319
Dettagli Esporta in BibTeX Esporta in EndNote
Limauro D, D'Ambrosio K, Langella E, De Simone G, Galdi I, Pedone C, Pedone E, Bartolucci S
* Exploring the catalytic mechanism of the first dimeric Bcp: Functional, structural and docking analyses of Bcp4 from Sulfolobus solfataricus (146 visite)
Biochimie (ISSN: 1638-6183, 0300-9084, 1638-6183electronic), 2010 Oct; 92(10): 1435-1444.
Impact Factor: 3.787
Dettagli Esporta in BibTeX Esporta in EndNote
Risitano AM, Seneca E, Marando L, Imbriaco M, Soscia E, Soscia F, Pizzuti LM, Malcovati L, Fenu S, Iori AP, Notaro R, Matarazzo M, Rotoli B
* From Renal Siderosis Due to Perpetual Hemosiderinuria to Possible Liver Overload Due to Extravascular Hemolysis: Changes in Iron Metabolism in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients On Eculizumab (189 visite)
Haematologica (ISSN: 0006-4971, 0006-6497, 0390-6078), 2009 Nov 20; 114(22): N/D-N/D.
Impact Factor: 10.555
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Limauro D, Pedone E, Galdi I, Pedone C, Bartolucci S, De Simone G
* Insights into the catalytic mechanism of the Bcp family: functional and structural analysis of Bcp1 from Sulfolobus solfataricus (185 visite)
Proteins (ISSN: 1097-0134, 0887-3585, 1097-0134electronic), 2009 Sep; 76(4): 995-1006.
Impact Factor: 3.085
Dettagli Esporta in BibTeX Esporta in EndNote
Limauro D, Pedone E, Galdi I, Bartolucci S
* Peroxiredoxins as cellular guardians in Sulfolobus solfataricus - characterization of Bcp1, Bcp3 and Bcp4 (178 visite)
Febs Journal (ISSN: 1742-464x), 2008 May; 275(9): 2067-2077.
Impact Factor: 3.139
Dettagli Esporta in BibTeX Esporta in EndNote
MAUREA S, LASTORIA S, CARACO C, INDOLFI P, CASALE F, DITULLIO M, SALVATORE M
IODINE-131-MIBG IMAGING TO MONITOR CHEMOTHERAPY RESPONSE IN ADVANCED NEUROBLASTOMA - COMPARISON WITH LABORATORY ANALYSIS (180 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 Sep; 35(9): 1429-1435.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
10 Records (9 escludendo Abstract e Conferenze).
Impact factor totale: 49.198 (38.643 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 45.233 (35.333 escludendo Abstract e Conferenze).
Impact factor totale: 49.198 (38.643 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 45.233 (35.333 escludendo Abstract e Conferenze).
Esporta in BibTeX Esporta in EndNote
Ultima modifica di Marco Comerci in data Thursday 19 March 2015, 12:37:16
168 visite. Ultima visita in data Friday 17 January 2020, 11:49:16
ibb.cnr.it